Structured evidence table for Seaweed Fiber Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Seaweed Fiber Gut Health Randomized Trial | Conclusions : This study provides the first clinical evidence in humans that whole H. | 2 | Lopez-Santamarina A (2025) | Modulation of Gut Microbiota by Whole Encapsulated Brown Seaweed (<i>Himanthalia elongata</i>) in Overweight Subjects: A Randomized Double-Blind Placebo-Controlled Trial. |
| Seaweed Fiber Gut Health Randomized Trial | Background/Objectives : Brown seaweeds, such as Himanthalia elongata , are a promising source of dietary fiber. | 2 | Lopez-Santamarina A (2025) | Modulation of Gut Microbiota by Whole Encapsulated Brown Seaweed (<i>Himanthalia elongata</i>) in Overweight Subjects: A Randomized Double-Blind Placebo-Controlled Trial. |
| Seaweed Fiber Gut Health Randomized Trial | elongata consumption on the gut microbiota composition and short-chain fatty acid production in overweight adults. | 2 | Lopez-Santamarina A (2025) | Modulation of Gut Microbiota by Whole Encapsulated Brown Seaweed (<i>Himanthalia elongata</i>) in Overweight Subjects: A Randomized Double-Blind Placebo-Controlled Trial. |
| Seaweed Fiber Gut Health Randomized Trial | Several studies indicated that soluble fiber can reduce serum cholesterol and glucose concentrations, as well as lower blood pressure, promote weight loss, improve insulin sensitivity and, consequently, contribute to improving metabolic syndrome and reducing morbidity and mortality associated with cardiovascular risk []. | 3 | Guerrero-Wyss Marion (2023) | Durvillaea antarctica : A Seaweed for Enhancing Immune and Cardiometabolic Health and Gut Microbiota Composition Modulation |
| Seaweed Fiber Gut Health Randomized Trial | 5 5 5 6 Metabolic syndrome is a group of disorders that occur in parallel and increase cardiovascular risk, that is, it involves a greater probability of developing coronary disease, stroke, and type 2 diabetes mellitus (T2DM) (10.4% national prevalence) []. | 3 | Guerrero-Wyss Marion (2023) | Durvillaea antarctica : A Seaweed for Enhancing Immune and Cardiometabolic Health and Gut Microbiota Composition Modulation |
| Seaweed Fiber Gut Health Randomized Trial | These disorders involve arterial hypertension (27.6%) and elevated cholesterol levels (27.8%) and plasma triglycerides (38.5%), but the basis of all of them is undoubtedly excess weight (73.2%) that generates insulin resistance and an increase in visceral adiposity, with its consequent increase in the cardiovascular risk [,]. | 3 | Guerrero-Wyss Marion (2023) | Durvillaea antarctica : A Seaweed for Enhancing Immune and Cardiometabolic Health and Gut Microbiota Composition Modulation |
| Seaweed Fiber Gut Health Randomized Trial | Durvillaea antarctica 1 1 2 , also called “cochayuyo”, is the seaweed that is the most consumed by the Chilean population; its consumption represents approximately 0.5 kg per capita. | 3 | Guerrero-Wyss Marion (2023) | Durvillaea antarctica : A Seaweed for Enhancing Immune and Cardiometabolic Health and Gut Microbiota Composition Modulation |
Source documents